Showing 2651-2660 of 3315 results for "".
- GenSight Reports Topline Efficacy and Safety Results at 3 Years Post-Treatment with Lumevoqhttps://modernod.com/news/gensight-reports-topline-efficacy-and-safety-results-at-3-years-post-treatment-with-lumevoq/2481464/GenSight Biologics reported topline efficacy and safety results at 3 years post-treatment administration in the REFLECT phase 3 clinical trial with Lumevoq (lenadogene nolparvovec). The results show sustained efficacy and favorable safety for bilateral intravitreal injection of the gene
- EyeBio Announces First Asset in Pipeline of Retinal Disease Treatments and Appoints New Members to Executive Teamhttps://modernod.com/news/eyebio-announces-first-asset-in-pipeline-of-retinal-disease-treatments-and-appoints-new-members-to-executive-team/2481448/Eyebiotech Limited announced several appointments to its executive team and announced details on Restoret, the first asset in a pipeline of multi-specific agonist antibodies. EyeBio announced the following appointments to the senior leadership team: Anthony P. Adami
- J&J Vision Receives CE Mark Approval for the ELITA Femtosecond Laser Systemhttps://modernod.com/news/jj-vision-receives-ce-mark-approval-for-the-elita-femtosecond-laser-system/2481440/Johnson & Johnson Vision has received CE Mark approval for the ELITA Femtosecond Laser System for laser vision correction. The new laser will allow surgeons to perform refractive correction on patients with myopia, with or without astigmatism, via a new lenticular procedure called t
- Ace Vision Group Appoints Cristos Ifantides, MD, as Director, Clinical Applications Developmenthttps://modernod.com/news/ace-vision-group-appoints-cristos-ifantides-md-as-director-clinical-applications-development/2481436/Ace Vision Group (AVG) announced the appointment of Cristos Ifantides, MD, MBA, as Director, Clinical Applications Development, effective immediately. In his new role, Dr. Ifantides will lead the education and clinical adoption efforts of AVG's forthcoming presbyopia technology
- Glaukos Submits NDA to FDA for iDose TRhttps://modernod.com/news/glaukos-submits-nda-to-fda-for-idose-tr/2481434/Glaukos announced the submission of a new drug application (NDA) to the FDA for iDose TR, a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time.&
- Study: Low Brain Pressure Could be a Risk Factor for Developing Glaucomahttps://modernod.com/news/study-low-brain-pressure-could-be-a-risk-factor-for-developing-glaucoma/2481431/An international team of researchers led by Lithuanian scientists provide additional evidence that intracranial pressure plays an important role in normal-tension glaucoma, which accounts for up to 50 percent of all glaucoma cases. A recent clinical
- Envision University Sets Agenda for In-Person Spring 2023 Conferencehttps://modernod.com/news/envision-university-sets-agenda-for-in-person-spring-2023-conference/2481426/The agenda has been set for the Envision Conference West, which will be held in collaboration with UT Health Department of Occupational Therapy, March 30-April 1, 2023, at the Academic Learning and Teaching Center of UT Health in San Antonio, Texas. The Envision Conference is the only multid
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development/2481420/Novel findings from researchers contradict previous notions about sugar's role in the onset of diabetic cataracts. The team of researchers, led by Prof. Ali Hafezi-Moghadam, MD, PhD, Director of the Molecular Biomarkers Nano-Imaging Laboratory (MBNI) at the Brigham and Wom
- Vision Expo East Announces Keynote Speakerhttps://modernod.com/news/vision-expo-east-announces-keynote-speaker/2481419/Vision Expo East announced that Jason Romero, a legally blind ultra-runner, will be the keynote speaker at the annual conference in New York City from March 16-19, 2023 (Education opens March 16; Exhibits open March 17). “After losing his vision to a dege
- Eylea Approved as First Pharmacologic Treatment of Preterm Infants with ROPhttps://modernod.com/news/eylea-approved-as-first-pharmacologic-for-treatment-of-preterm-infants-with-rop/2481400/The FDA has approved Eylea (aflibercept) to treat preterm infants with retinopathy of prematurity (ROP). Following this first pediatric approval, Eylea is now indicated to treat five retinal conditions caused by ocular angiogenesis. “Retinopathy of prematurity is a leadi